Order Article Reprints

Corino VDA, Bologna M, Calareso G, Licitra L, Ghi M, Rinaldi G, Caponigro F, Morelli F, Airoldi M, Allegrini G, et al. A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study. Diagnostics. 2021; 11(6):979. https://doi.org/10.3390/diagnostics11060979

Corino, Valentina D. A., Marco Bologna, Giuseppina Calareso, Lisa Licitra, Mariagrazia Ghi, Gaetana Rinaldi, Francesco Caponigro, Franco Morelli, Mario Airoldi, Giacomo Allegrini, and et al. 2021. "A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study" Diagnostics 11, no. 6: 979. https://doi.org/10.3390/diagnostics11060979

Corino, V. D. A., Bologna, M., Calareso, G., Licitra, L., Ghi, M., Rinaldi, G., Caponigro, F., Morelli, F., Airoldi, M., Allegrini, G., Cassano, A., Ferrari, D., Mirabile, A., Tosoni, A., Galizia, D., Merlano, M., Sponghini, A., Moretti, G., Mainardi, L., & Bossi, P. (2021). A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study. Diagnostics, 11(6), 979. https://doi.org/10.3390/diagnostics11060979